Abstract
A new group of antidiabetic drugs - also called SGLT2 inhibitors glifloziny - offers new treatment possibilities 2 diabetes and type 1. The first group of representatives, which was filed in Europe for clinical use, is dapagliflozin, others were kanagliflozin and empagliflozin.
In the foreseeable future it will be several other representatives, including ertugliflozinu.